WHO Raises Alert Over Critical Shortage of Obesity Jabs

Less than one in 10 individuals eligible to benefit from obesity jabs such as Wegovy are able to get them, states the global health agency as it releases its initial recommendations on the drugs.

Considering more than one billion people worldwide currently classified as obese, it is advocating for more widespread and fairer availability to these injectable treatments.

Based on forecasts, more than two billion are projected to be obese by 2030 if no action is taken.

"The latest guidance recognises that obesity is a long-term condition that can be treated with thorough and lifelong care," remarked the agency's head Tedros Adhanom Ghebreyesus.

Substantial prices, insufficient output, and supply-chain constraints are key barriers to widespread access to the treatments that can aid individuals in losing significant body mass, notes the organization.

GLP-1 Therapy Shortage

Despite the current most optimistic scenario, the supply of these medications would only suffice for around 100 million people – fewer than 10% of those who need them, according to the health organization.

The recommendation encourages nations and manufacturers to increase access, via measures including licensing agreements.

Exclusive production rights on a key compound – the primary component of Novo Nordisk's Wegovy – is set to lapse in a number of countries in 2026.

The Way Weight-Loss Injections Operate

GLP-1 drugs imitate a natural hormone to delay gastric emptying, reduce hunger and enhance satiety so individuals consume fewer calories.

Patients usually see weight reduction after several weeks of starting on the weekly injections.

Research indicates users may regain a significant portion a year later of stopping the treatment, as their usual appetite return.

Being carrying excess weight increases your risk for contracting diseases, like type 2 diabetes, heart disease, stroke, and specific cancers.

Obesity affects people in every country and was linked to millions of deaths worldwide in 2024, per the health agency.